JP2025529240A5 - - Google Patents

Info

Publication number
JP2025529240A5
JP2025529240A5 JP2025513127A JP2025513127A JP2025529240A5 JP 2025529240 A5 JP2025529240 A5 JP 2025529240A5 JP 2025513127 A JP2025513127 A JP 2025513127A JP 2025513127 A JP2025513127 A JP 2025513127A JP 2025529240 A5 JP2025529240 A5 JP 2025529240A5
Authority
JP
Japan
Prior art keywords
cell lymphoma
pharmaceutical composition
composition according
lymphoma
combination drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025513127A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025529240A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/060652 external-priority patent/WO2024047394A1/en
Publication of JP2025529240A publication Critical patent/JP2025529240A/ja
Publication of JP2025529240A5 publication Critical patent/JP2025529240A5/ja
Pending legal-status Critical Current

Links

JP2025513127A 2022-08-31 2022-11-04 トリナパント、セダズリジン及びデシタビンによるｔ細胞リンパ腫の治療のための併用療法 Pending JP2025529240A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263374137P 2022-08-31 2022-08-31
US63/374,137 2022-08-31
PCT/IB2022/060652 WO2024047394A1 (en) 2022-08-31 2022-11-04 Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine

Publications (2)

Publication Number Publication Date
JP2025529240A JP2025529240A (ja) 2025-09-04
JP2025529240A5 true JP2025529240A5 (https=) 2025-11-05

Family

ID=84359488

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025513127A Pending JP2025529240A (ja) 2022-08-31 2022-11-04 トリナパント、セダズリジン及びデシタビンによるｔ細胞リンパ腫の治療のための併用療法

Country Status (9)

Country Link
US (1) US20240082286A1 (https=)
EP (1) EP4580635A1 (https=)
JP (1) JP2025529240A (https=)
KR (1) KR20250053870A (https=)
AU (1) AU2022476674A1 (https=)
CA (1) CA3266274A1 (https=)
MX (1) MX2025002312A (https=)
TW (1) TW202410893A (https=)
WO (1) WO2024047394A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122022015241B1 (pt) 2013-12-20 2023-09-26 Astex Therapeutics Limited Compostos heterocíclicos bicíclicos intermediários para a preparação de um composto de fórmula (i)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
BR122022015241B1 (pt) 2013-12-20 2023-09-26 Astex Therapeutics Limited Compostos heterocíclicos bicíclicos intermediários para a preparação de um composto de fórmula (i)
US12239653B2 (en) * 2020-02-25 2025-03-04 Taiho Pharmaceutical Co., Ltd. Combination decitabine and cedazuridine solid oral dosage forms

Similar Documents

Publication Publication Date Title
US11013698B2 (en) Combinations of LSD1 inhibitors for the treatment of hematological malignancies
KR101716804B1 (ko) 항종양 알칼로이드를 이용한 병용요법
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
JP2012521435A5 (https=)
CA2712747A1 (en) Combinatory cancer treatment
JP2021523114A5 (https=)
CZ301482B6 (cs) Prostredky a použití ET743 k lécbe rakoviny
EP2177223A2 (en) Homoharringonine alone or combined with other agents for use in treating chronic myelogenous leukemia resistant or intolerant to sti571
JP2023543211A5 (https=)
JP2025529240A5 (https=)
JP2008501038A5 (https=)
RU2346686C2 (ru) Комбинации, включающие эпотилоны и антиметаболиты
KR20150090091A (ko) 볼라세르티브와의 병용 요법
Foss Overview of cutaneous T-cell lymphoma: prognostic factors and novel therapeutic approaches
ES2348140T3 (es) Combinación de un análogo de mostaza nitrogenada y de imatinib para el tratamiento de la leucemia linfocítica crónica.
CN111163781B (zh) 用于治疗癌症的mdm2抑制剂与erk抑制剂的组合
JP2019522030A5 (https=)
RU2025107488A (ru) Комбинированные терапии для лечения т-клеточных лимфом с помощью толинапанта, цедазуридина и децитабина
JP2006508118A5 (https=)
JP2024531799A5 (https=)
TW201909918A (zh) BET抑制劑及Bcl-2抑制劑之組合療法
IL300145A (en) A combination of a BCL-2 inhibitor and a hypomethylating agent for the treatment of cancer, its uses and pharmaceutical preparations
Robak et al. The Comparison of 2-Chlorodeoxyadenosine (2-Cd A) in Combination with Interferon α (IFN α) or Interferon γ (IFN γ) on Granulocyte-Macrophage Progenitor Cells (CFU-GM) and Clonogenic Blasts in (CFU-L) In Vitro Cultures
JP2024524288A5 (https=)
Ardeshna et al. A case of psoriasis vulgaris aggravated with atorvastatin, aided by concomitant cyclosporine